Yellowbird Diagnostics is a clinical-stage company developing novel plug-and-play diagnostic agents to enhance disease detection in standard imaging procedures. Our lead asset is a radiopharmaceutical currently in Phase I clinical trials, following remarkable first-in-human compassionate use data. This asset will redefine the PET imaging landscape. Yellowbird also has two other pre-clinical assets being developed.